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Methods: The study compared patients who died in-hospital to those who survived to
discharge in a cohort of 93 patients meeting strict definitions for CS to identify correlates
associated with mortality.
Results: The overall in-hospital mortality rate for the study cohort was 33%. The
baseline characteristics were balanced except for older average age and left ventricular
ejection fraction in those who died (p0.049 and p0.014, respectively). As detailed in
the Table, the insertion of IABP pre-PCI, cardiac arrest at the catheterization lab, and
lower ejection fraction (EF) were all correlated with in-hospital mortally (odd ratios 2.68,
5.93 and 0.02, respectively).
Conclusions: In the era of PPCI and IABP as standard of care in AMI complicated by
CS, patients with low EF, those who necessitate IABP insertion pre-PCI and those who
necessitated CPR during PCI are at higher risk for in-hospital mortality and should be
considered for more robust devices (e.g. assisted devices) with an attempt to improve their
prognosis.
Table 1. The demographic and clinical characteristics of patients with





Upper OR P Value
Age 1.04 1-1.07 0.053
Men 0.87 0.35-2.15 0.756
Diabetes mellitus 1.23 0.5-3.01 0.646
Body mass index 0.91 0.83-1 0.059
Ejection fraction (%) 0.02 0-0.5 0.018
Number of diseased vessels 1.54 0.92-2.6 0.102
IABP pre PCI 2.68 1.11-6.52 0.029
Pre-hospital CS 0.183 0.76-4.33 1.81




Comparison Of Outcomes Of Patients Presenting With Inferior STEMI With Proximal
And Distal Right Coronary Artery Obstruction
Manu Kaushik, Alok Saurav, Satish Chandraprakasam, Anand Deshmukh,
Michael Del Core, Aryan Mooss, Dennis Esterbrooks
Creighton University School of Medicine, Omaha, NE
Background: While, proximal right coronary artery (RCA) occlusion in patients with
inferior STEMI would suggest right ventricular involvement, the effect of location of
RCA occlusion on outcomes has not been studied. We sought to evaluate the impact of
site of occlusion of RCA on outcomes of patients with inferior STEMI undergoing PCI.
Methods: All patients presenting to a tertiary care center between June 2006 and May
2012 with STEMI and undergoing PCI with RCA as the culprit vessel were included.
Patients with proximal RCA occlusion were compared to patients with distal RCA
occlusion. Lesion location was determined based on whether the occlusion was proximal
or distal to major right ventricular branch take-off. Patients with posterior descending
branch or posterolateral branch occlusion were excluded to correct for left ventricular
myocardium at risk in both comparison groups. Clinical and outcome variables were
retrieved from retrospective chart review.
Results: One hundred, ninety-seven patients were included in final analysis of which, 94
patients had proximal RCA and 103 had distal RCA occlusion. There were no significant
differences between the two groups with respect to gender, prevalence of hypertension,
hyperlipidemia (HL), diabetes mellitus (DM), smoking, chronic pulmonary disease and
timely revascularization. Twenty-four patients were treated with PTCA, while 173
patients were treated with stenting. Major adverse cardiovascular events (MACE) defined
as combined incidence of cardiogenic shock, IABP use, cardiac arrest and death was
similar in the two groups (21.3% vs. 18.4%; p 0.05). Individual event rates for
cardiogenic shock, IABP use, death, cardiogenic shock and hypotension were also
statistically similar in both groups. Post STEMI left ventricular function was similar in
both groups (46.8 vs 47.2%; p 0.77) as was the duration of hospitalization (5.06 vs. 5.17
days; p 0.75). No clinical variables (gender, hypertension, DM, smoking, HL, chronic
pulmonary disease, etc.) predicted MACE. However, time to revascularization 6 hours
from symptom onset showed a statistical trend towards predicting MACE (OR0.50
[95% CI 0.24-1.05], p  0.06).
Conclusions: In patients presenting with inferior STEMI treated with PCI, location of
occlusion with respect to the right ventricular branch origin does not predict major adverse
cardiovascular events Proximal lesion location in right coronary artery should not be used
as a surrogate for clinically significant right ventricular involvement in STEMI patients.
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Prediction Of Multivessel Disease In STEMI Patients
Eric Bansal, Nazila Rad, Andres Cortes, Brittany Wagman, Kenneth Kita, Han Tun,
Ray Matthews, Anilkumar Mehra, Michael Gaglia, Leonardo Clavijo, David Shavelle
University of Southern California, Los Angeles, CA
Background: Although early loading of antiplatelet therapy is beneficial for STEMI
patients, it may cause bleeding complications in patients with multivessel coronary artery
disease (MVD) requiring coronary artery bypass surgery. The identification of MVD in
STEMI patients using the initial electrocardiogram (ECG) would be beneficial. We
therefore investigated the ability of the initial ECG to predict MVD in STEMI patients.
Methods: From January, 2008 through December, 2010, 224 patients undergoing
primary PCI for STEMI were evaluated. Baseline demographics, ECG findings,
angiographic findings and in-hospital clinical events were collected. ECG findings
included the amount of ST segment elevation and/or depression in mm in all ECG leads
and the total number of leads with  1 mm ST segment elevation and/or ST segment
depression. MVD was defined as  2 coronary vessels with  70% luminal diameter
stenosis; single vessel disease (SVD) was defined as 1 coronary vessel with 70% luminal
diameter stenosis. Patients with SVD (n106) were compared to those with MVD
(n118) and predictors of MVD disease were evaluated using multiple logistic regression
analysis.
Results: Patients with MVD had a higher prevalence of hypertension, hyperlipidemia,
diabetes mellitus, metabolic syndrome and a family history of CAD compared to those
with SVD. The left anterior descending artery was more commonly the infarct related
artery in patients with SVD compared to the right coronary artery in patients with MVD.
In-hospital MACE rates were significantly higher in patients with MVD compared to
those with SVD, 30.5% versus 17.9%, p 0.03, respectively. Hyperlipidemia, hypertension,
diabetes mellitus, total ST segment changes 6 mm and total number of ECG leads with
 1 mm ST segment depression predicted the presence of MVD. After adjusting for age
and gender, more than 3 ECG leads with  1 mm of ST segment depression predicted
the presence of MVD, odds radio 3.79 (95% CI 1.2 to 12.3, p 0.03).
Conclusions: STEMI patients with MVD can be identified based upon the initial
ECG.
CRT-31
Total Bilirubin Predicts Long Term Clinical Outcomes In No-reflow Patients With
Acute St-segment Elevation Myocardial Infarction During Primary Coronary
Intervention
liu jiangfeng, Sr., Chen Yundai, wang changhua, tian feng, yang junjie, zhang tao
Chinese PLA General Hospital, Beijing, China
Background: Increased oxidative stress and vascular inflammation are main mechanisms
for no reflow onset after acute ST-segment elevation myocardial infarction(STEMI) who
were treated by primary percutaneous coronary intervention (PCI). Recent studies have
been reported that the concentration of total bilirubin (TB), acted as antioxidant, could
preserve coronary flow reserve and coronary microvascular functions and was reversely
associated with in hospital outcomes of primary PCI. However, it is not clear whether
high TB exert favorable effects on prognosis of no reflow patients during PCI. This study
was performed to assess the prognostic role of TB in no reflow patients.
Material and Methods: 143 consecutive patients (age: 65.2912.62 years old) with no
reflow treated by primary PCI was enrolled to study. Patients were divided into two
groups based on the TB concentrations (0.9 mg/dl). No-reflow was diagnosed using 2
different methods after PCI: TIMI flow Grade2 or TIMI flow grade 3 with a TIMI
myocardial perfusion grade(TMPG)1. All patients were retrospectively followed up for
9 years for the all cause death and cardiac death.
Results: There were 31 all cause deaths during follow-up. Of them, 26 patients died
from cardiac cause. Patients with adverse events had lower baseline serum TB levels
(P0.05). All patients were stratified into high TB and low TB groups. The mortality of










high TB group is lower than that of low TB group (14.9% vs. 29.0% for all cause death,
P0.038; 9.5% vs. 27.5% for cardiac death, p0.006). In a multivariate Cox regression
analysis,after adjusted for age, left ventricular ejection fraction (LVEF) et al., the patients
had the lower incidence of all cause death and cardiac death in the high TB group than
that in the low TB group (OR:0.423, 95%CI 0.184-0.975,p0.043, vs. OR: 0.281,
95%CI 0.103-0.765, P0.013, respectively).
Conclusions: Serum high TB level on admission is a protective and independent
predictor of long term outcomes among no-reflow patients with STEMI undergoing
primary PCI. In addition, TB concentrations may be a novel candidate biomarker for
stratification of risk in no reflow patients with STEMI during primary PCI.
Antiplatelet Therapy
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Universal Ticagrelor Versus Assay-Driven Antiplatelet Therapy in Acute Coronary
Syndrome Patients: A Cost-Effectiveness Analysis
Brendan L. Limone,1 Craig I Coleman2
1Hartford Hospital, Hartford, CT; 2University of Connecticut, Storrs, CT
Background: Assays have been developed to monitor on-P2Y12 platelet reactivity, and
these tests can accurately predict which patients will have poor response to clopidogrel.
We sought to determine the cost-effectiveness of using a platelet reactivity assay to aid in
the selection between ticagrelor and clopidogrel based dual antiplatelet therapy in ACS
patients.
Methods: A hybrid decision tree/Markov model was used to calculate 5 year costs (2011
US$), quality adjusted life years (QALYs) and incremental cost-effectiveness ratios
(ICERs) of 1 year of platelet reactivity assay-driven ticagrelor (given to patients with high
platelet reactivity defined as 230 on the VerifyNow P2Y12 assay, Accumetrics, San
Diego, CA, others got generic clopidogrel) or universal (given to all patients) ticagrelor.
We assumed a cohort of 65 year old ACS patients and 32% and 13% incidences of high
platelet reactivity at discharge and at 1 month. The analysis was conducted from a US
payer perspective and used a 1 year cycle length. Data depicting the efficacy and safety of
ticagrelor and clopidogrel were taken from multinational randomized trials.
Results: Patients experiencing an acute coronary event treated with ticagrelor or
clopidogrel based upon the results of the platelet reactivity assay lived an average of 3.497
QALYs at a treatment cost of $30,615. Those receiving universal ticagrelor lived an
average of 3.530 QALYs and incurred costs of $32,865 (ICER for universal ticagrelor
$68,182/QALY). Universal ticagrelor was not cost-effective unless the yearly cost of
ticagrelor was$2,800, the yearly cost of clopidogrel rose above $1,100 or the hazard ratio
for death on ticagrelor vs. clopidogrel was 0.74. Monte Carlo simulation suggested
universal and platelet reactivity assay-driven selection of ticagrelor would have
ICERs$50,000/QALY (be cost-effective) in 26% and 74% of 10,000 iterations,
respectively.
Conclusion: Universal ticagrelor was not cost-effective compared to platelet reactivity
assay-driven use of ticagrelor or clopidogrel. In the age of generic clopidogrel, assay-driven
selection of antiplatelet therapy appears to be a reasonable strategy to decrease ACS
associated healthcare costs.
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Peri-procedural CK-MB Levels In Percutaneous Coronary Intervention With High-
dose Bolus Tirofiban Vs. Abciximab Plus Either Unfractionated Heparin Or
Bivalirudin: An Analysis From TENACITY
Peter B. Berger,1 Michael C. Janzen,2 Steven V. Manoukian3
1Geisinger Center for Clinical Studies, Danville, PA; 2Medicure Inc., Winnipeg, MB,
Canada 3Sarah Cannon Research Institute, Nashville, TN
Background: TENACITY was a randomized 2 2 factorial trial comparing high-dose
bolus (HDB) tirofiban vs. abciximab, and unfractionated heparin (UFH) vs. bivalirudin,
in patients undergoing percutaneous coronary intervention (PCI). The primary endpoint
of 30-day death, myocardial infarction, or urgent target vessel revascularization occurred
in 6.9% and 8.8% of patients randomized to HDB tirofiban and abciximab, respectively.
In this analysis, we retrospectively analyzed CK-MB levels in the 4 arms of the study.
Methods: Serial CK-MB samples were obtained in 380 of the 383 enrolled patients.
Results: A non-inferiority analysis with margin of 2 ng/mL was performed using
PROC TTEST of SAS version 9.2, with HDB tirofiban and abciximab study arms
pooled across levels of UFH and bivalirudin. The non-inferiority of HDB tirofiban vs.
abciximab was established from a one-sided test for the difference in peak CK-MB
means (p-value  0.011), with a corresponding 90% confidence interval of (0.52,














Median Peak CK-MB 2.6 2.6 2.7 2.5
Peak CK-MB Percentile
25-75
1.6-6.4 1.3-5.5 1.3-6.4 1.4-5.6
Median CK-MB from
serial draw #1
1.5 1.5 1.6 1.4
Median CK-MB from
serial draw #2
1.8 1.8 1.8 1.8
Median CK-MB from
serial draw #3
2.1 2.2 2.2 2.1
Median CK-MB from
serial draw #4
2.2 2.3 2.3 2.3
Median CK-MB from
serial draw #5
2.5 3.1 3.5 2.3
ATUFH or bivalirudin; GPItirofiban or abciximab.
Conclusions: CK-MB levels are similar after the administration of HDB tirofiban and
abciximab, and UFH and bivalirudin, in this prematurely terminated, undersized trial.
These data do suggest, however, that HDB tirofiban and abciximab, and UFH and
bivalirudin, may be similar in their ability to prevent peri-procedural myocardial infarction
in moderate to high-risk patients undergoing PCI. These data should be useful in
identifying the size of an appropriately powered trial necessary to compare these regimens.
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Outcomes Of Anti-platelet Therapy For Acute Coronary Syndromes Patients Directed
By Post Pci Platelet Function Testing In A Real World Setting
Elad Asher, Perry Anarado, Myttle Mayuga, Martin Bradley, Ka Chun Alan Chan,
Isidore Okere, Darwin Jeyaraj, Daniel I. Simon, Tom Lassar
Harrington Heart & Vascular Institute, Case Medical Center, University Hospitals,
Cleveland, OH
Objectives: To assess whether Accumetrix VerifyNow P2Y12 testing directed anti-
platelet therapy after acute coronary syndromes (ACS) percutaneous coronary intervention
(PCI) in a real world setting, could affect outcomes.
Background: Multiple trials suggest that high residual on-treatment platelet reactivity
(HRPR) [Platelet Reactivity Units (PRU)230] increases the incidence of major adverse
cardiac events: death, myocardial infarction, target vessel revascularization and stent
thrombosis (MACE). Data on routine real world testing of ACS patients is lacking.
Methods: 371 ACS patients had PCI and platelet function testing after initial
background aspirin and  600 mg of clopidogrel. For PRU at 12-24 hours  230,
maintenance 325 mg/day of aspirin and 75 or 150 mg/day of clopidogrel for 1 week then
75 mg/day were continued unless followup testing at 1-3 weeks demonstrated HRPR.
Most patients with initial HRPR were switched to prasugrel or ticagrelor with no further
testing, as hyporesponse is rare; or clopidogrel 150 mg/day with repeat testing at 1-3
weeks. Continued HRPR on clopidogrel usually drove switching to prasugrel or ticagrelor
unless contraindicated.
Results: There were 148 (40%) HRPR and 223 (60%) responders patients. MACE was
similar between the two groups [5/148 (3.4%) vs. 6/223 (2.7%), respectively, p0.76].
Even after subdividing ACS to unstable angina (UA) and Non ST elevation MI
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